COUNTERPOINT: The Role of Stem Cell Transplantation in Mantle Cell Lymphoma
December 15th 2016Management strategies for patients with mantle cell lymphoma continue to demonstrate pendulum-like swings between those appropriate for low-grade lymphoma, and those appropriate for very aggressive lymphoma.
Releasing the Brake on the Immune System: The PD-1 Strategy for Hematologic Malignancies
June 15th 2015Incorporation of PD-1 blockade into the treatment algorithms for hematologic malignancies is currently being pursued in multiple active clinical trials. Here we review the data on anti–PD-1 monoclonal antibodies to date and discuss ongoing and future clinical trials.
Cancer Management Chapter 27: Non-Hodgkin lymphoma
March 12th 2010The incidence rates of non-Hodgkin lymphoma (NHL) in the United States have almost doubled between 1970 and 1990, representing one of the largest increases of any cancer. Although the overall incidence rates of NHL began to stabilize in the late 1990s, the temporal trends varied by histologic subtype. Some of this increase may be artifactual, resulting from improved diagnostic techniques and access to medical care, or directly related to the development of NHL in 25- to 54-year-old men with human immunodeficiency virus (HIV) infection. However, additional factors must be responsible for this unexpected increase in frequency of NHL that has been observed throughout the United States.
Radioimmunotherapy: A New Treatment Modality for B-Cell Non-Hodgkin’s Lymphoma
May 1st 2004Yttrium-90 (Y-90) ibritumomabtiuxetan (Zevalin) radioimmunotherapywas approvedby the US Food and DrugAdministration (FDA) in February2002 and tositumomab/iodine-131(I-131) tositumomab (Bexxar) was approvedby the FDA in June 2003 forthe treatment of patients with relapsedor refractory low-grade, follicular, orCD20-positive transformed B-cellnon-Hodgkin’s lymphoma (NHL),and rituximab (Rituxan)-refractoryfollicular NHL. In this excellentreview, Drs. Ghobrial and Witzigdescribe the rationale for radioimmunotherapyand the relevant clinicaltrials that formed the basis forFDA approval.